Calidi Biotherapeutics, Inc. (CLDI) Fair Value 2026

CLDI · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

4.3 /10

32 fundamental signals · 2 models active

Value Trap Risk

WARN (56/100)

Quick Summary — As of 2026-08-28, Calidi Biotherapeutics, Inc. (CLDI) trades at $1.32, versus a $4.77 median fair value across its 2 active models — 261.6% above the current price. QOC: 4.3/10. Value Trap Risk: 56/100 (WARN). 2/13 models active.

Key Facts

Ticker
CLDI
Price
$1.32
Quality Score
4.3/10
Value Trap Risk
56/100
Models Active
2/13
Last Updated
Strength: ML-RIV suggests +458.1% upside with 53% confidence
Risk: Value Trap score of 56 suggests caution despite apparent undervaluation

Is Calidi Biotherapeutics, Inc. (CLDI) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, Calidi Biotherapeutics, Inc. (CLDI) appears undervalued as of : the median of 2 independent fair value estimates is $4.77, 261.6% above the current price of $1.32. Estimates range from $2.18 to $7.37. CLDI scores 4.3/10 on fundamental quality and 56/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.4% versus its own 13-model consensus, across 3,809 rated companies as of 2026-08-28. CLDI’s +261.6% gap is wider than that market norm, and the Biotechnology sector median is -64.7%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Calidi Biotherapeutics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give CLDI?

2 Intrinsic Value Models vs. Current Price ($1.32)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $7.37 +458.1%
Option-Based · Medium Conviction
 $2.18 +65.2%

All Models Active

All 2 models are displayed above.

What Is Calidi Biotherapeutics, Inc. (CLDI) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Calidi Biotherapeutics, Inc. is potentially undervalued at its current price of $1.32. Based on our 13-model framework, Calidi Biotherapeutics, Inc.'s intrinsic value is estimated at a median fair value of $4.77 — representing +261.6% implied upside — with 2 out of 2 active models confirming this thesis. Model dispersion is worth noting: ML-RIV targets $7.37 (+458.1%), versus PWERM at $2.18 (+65.2%). This +393.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About CLDI?

2 of 13 models are currently active for CLDI. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for CLDI is $4.77 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does CLDI Rank in Biotechnology?

Among 625 Biotechnology stocks, CLDI ranks #494 by Quality of Company score. CirclFi's QOC score of 4.3/10 evaluates 32 fundamental signals. A score of 4.3 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For Calidi Biotherapeutics, Inc., metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is CLDI a Value Trap?

CirclFi's Value Trap algorithm assigns CLDI a score of 56/100 (WARN). This is a warning signal. Additional research into recent 10-Q filings is recommended. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for Calidi Biotherapeutics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, Calidi Biotherapeutics, Inc. scores 4.3 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +393.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every CLDI valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across CLDI's 2 active models, average confidence is 42%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Calidi Biotherapeutics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

FBRXForte Biosciences, Inc.QOC 4.3ENVBEnveric Biosciences, Inc.QOC 4.3SMNRSemnur Pharmaceuticals, Inc.QOC 4.3CRBPCorbus Pharmaceuticals Holdings, Inc.QOC 4.3CDTCDT Equity Inc.QOC 4.3DCOYDecoy Therapeutics Inc.QOC 4.3TBPHTheravance Biopharma, Inc.QOC 8.2GOVXGeoVax Labs, Inc.QOC 5.7ALGSAligos Therapeutics, Inc.QOC 4.9EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: FBRX · ENVB · SMNR · CRBP · CDT · DCOY · TBPH · GOVX · ALGS · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to CLDI?

6 companies across all industries closest to CLDI’s Quality of Company score of 4.3/10.

SATTSativus Tech Corp.QOC 4.3RGNTRegentis Biomaterials Ltd.QOC 4.3MEDSDataMEDS AI, Inc.QOC 4.3NXENexGen Energy Ltd.QOC 4.3KRFGKing Resources, IncQOC 4.3NVDANVIDIA CorporationQOC 10.0

Read investment analysis: SATT · RGNT · MEDS · NXE · KRFG · NVDA

Where Does CLDI Sit in CirclFi's Biotechnology Rankings?

CLDI is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About Calidi Biotherapeutics, Inc.’s Valuation?

What is Calidi Biotherapeutics, Inc.'s intrinsic value in 2026?

CirclFi puts Calidi Biotherapeutics, Inc. (CLDI)'s intrinsic value at $4.77 — the median of 2 independent model estimates as of 2026-08-28, ranging from $2.18 to $7.37. The Quality of Company score is 4.3/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is CLDI overvalued or undervalued right now?

At $1.32, 2 of 2 active models suggest CLDI may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $4.77, 261.6% above the current price of $1.32 — a consensus view that CLDI is undervalued. The assessment depends on which methodology best fits Calidi Biotherapeutics, Inc.'s business model in Biotechnology.

What does a Quality of Company score of 4.3 mean for CLDI?

Calidi Biotherapeutics, Inc.'s QOC of 4.3/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores below 5 flag potential fundamental weaknesses requiring careful analysis.

How many valuation models does CirclFi run on CLDI?

CirclFi analyzes CLDI with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is CLDI a value trap in 2026?

Calidi Biotherapeutics, Inc.'s Value Trap score is 56/100 (WARN). This elevated score suggests the stock may look undervalued but faces deteriorating fundamentals — declining margins, rising debt, or shrinking revenue could make the apparent discount deceptive. Browse our ranked stock lists to compare value-trap scores across industries. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, Calidi Biotherapeutics, Inc. (CLDI) has a median fair value of $4.77 — 261.6% above the current price of $1.32 — as of 2026-08-28.” Source: circlfi.com/stock/CLDI/ · Methodology
Primary sources for this CLDI valuation
  • Financial statements: Calidi Biotherapeutics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001855485) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for CLDI as of ; valuations recomputed .